PULM Pulmatrix Corporation: מקדם חוב לטווח ארוך להון

Pulmatrix, Inc. (PULM) price action depends on the outcomes of the PUR1900 tests and the potential of the iSPERSE platform. The foundation is based on innovations in inhalation delivery, although the early stage of development creates binary risks. The long-term financial leverage ratio visualizes the dependence of borrowed funds on equity, with the latest parameter standing at 0.00, which determines the company's current debt sustainability.

As Pulmatrix, Inc. (PULM) develops its innovative iSPERSE platform for the treatment of rare diseases, the company requires strategic financing. This long-term debt capital coverage ratio compares obligations with maturities exceeding one year against equity. An increase in this indicator signals higher financial leverage to accelerate commercialization, while declining values suggest a conservative approach to borrowing. This determines the company's resilience to market shocks.